FY4/18
Supplementary Materials

June 5, 2018

１．Consolidated Results■Year-on-Year
FY4/17
results

FY4/18results

YoYchange(¥ million)
YoYchange(%)

Net sales

248,110

268,385+20,275+8.2

Gross profit

42,092

47,993+5,90117.0

17.9+14.0% of net sales

27,52928,370+841

11.1

10.6

+3.1

14,563

19,622+5,059

5.9

7.3

+34.7

15,08020,129+5,049

6.1

7.5

+33.5

7,949

10,567+2,618

+32.9

3.2

3.9

250.71310.08+59.37+23.7

SG&A expenses% of net sales

Operating income% of net sales

Ordinary income% of net sales

Profit attributableto owners of parent% of net sales

Earnings pershare(¥)

Figures in the table are rounded down

■Vs Plan

FY4/18plan

FY4/18results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

267,500

268,385+885+0.3

Gross profit

47,40047,993+593+1.3% of net sales

17.7

17.9

29,40028,370(1,030)

(3.5)

11.0

10.6

18,00019,622+1,622

+9.0

6.7

7.3

18,50020,129+1,629

+8.8

6.9

7.5

9,200

10,567+1,367+14.93.43.9269.96

310.08+40.12+14.9

SG&A expenses% of net sales

Operating income% of net sales

Ordinary income% of net sales

Profit attributableto owners of parent% of net sales

Earnings pershare(¥)

Figures in the table are rounded down

-1-２. Segment Information（Dispensing Pharmacy Business）■Year-on-Year
FY4/17
results

FY4/18results

YoYchange(¥ million)
YoYchange(%)

Net sales

221,801

238,645+16,844+7.6

Gross profit

32,09036,030+3,940+12.3% of net sales

14.5

15.1

13,432

14,034+60+4.5

6.15.918,658

21,995+3,337+17.9

8.4

9.2

19,11022,668+3,558

+18.6

8.6

9.5

SG&A expenses% of net sales

Operating income% of net sales

Segment income% of net sales

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income■Vs Plan
FY4/18plan

FY4/18results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

237,900

238,645+745+0.3

Gross profit

35,26036,030+770+2.2% of net sales

14.8

15.1

14,86014,034(826)

(5.6)

6.2

5.9

20,40021,995+1,595+7.8

8.6

9.2

21,00022,668+1,668

+7.9

8.8

9.5

SG&A expenses% of net sales

Operating income% of net sales

Segment income% of net sales

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income-2-3. Segment Information（Cosmetic and Drug Store Business）■Year-on-Year
FY4/17
results

FY4/18results

YoYchange(¥ million)
YoYchange(%)

Net sales

21,38324,117+2,734+12.8

Gross profit7,623

8,925+1,302+17.1% of net sales

35.6

37.0

8,583

8,317(266)

(3.1)

40.1

34.5(959)-

608+1,567-

(866)
-

657+1,523-

SG&A expenses% of net sales

Operating income% of net sales

Segment income% of net sales

2.5

2.7

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income■Vs Plan
FY4/18plan

FY4/18results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

23,60024,117+517+2.2Gross profit

8,680

8,925+245+2.8% of net sales

36.8

37.0

8,430

8,317(113)(1.3)% of net sales

35.7

34.5

Operating income+358+143.2+377+134.6

SG&A expenses

250608% of net sales

1.1

2.5

Segment income

280

657

% of net sales

1.2

2.7

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income-3-

4. Sales Verification■Dispensing Pharmacy (YoY）
Net sales
Same store (814)Store openings in theprevious year (176)

Total (1,029)（%）（%）■Dispensing Pharmacy（Vs Plan）
Average
Average
Prescription
Prescription
Net salesprescription
prescription
volumevolumeprice
price+1.5+0.2+1.4

Same store (814)+0.4(0.0)+0.4+100.8+94.5+3.9

Store openings in theprevious year (176)+4.4+0.6+3.8+7.9+7.6+0.2

Total (1,029)+0.4(1.1)+1.6■Cosmetic and Drug Store（YoY）
Net sales
Same store (35)Store openings in theprevious year (9)Total (48)（%） ■Cosmetic and Drug Store (Vs Plan）

Average
Number ofspending percustomerscustomer

Net sales（%）

Average
Number ofspending percustomers
customer+8.7+3.2+5.3

Same store (35)+2.2+1.5+0.7+288.6+221.9+20.7

Store openings in theprevious year (9)+10.0+3.5+6.3+12.8+4.9+7.5+2.2+0.8+1.4

Total (48)-4-

5. Consolidated Balance Sheet■Assets(¥ million)

End-FY4/16

End-FY4/17

End-FY4/18

Change22,647
12,385
10,98456,593
14,694
9,537
1,352

29,775
9,990
11,66865,42015,365
9,958
1,166

63,77910,466
9,580
96,16914,934
10,041
824+34,004+476(2,088)+30,749(431)+83(342)

28,15328,46427,853(611)

33,337
13
35,586
2,677
2,038
10,01340,9398
43,1092,435
2,167
10,44338,011
11
40,132
2,375
2,216
11,339(2,928)+3(2,977)(60)+49+896

19,55519,32919,176(153)

Total assets

83,294
139,888

90,902
156,323

103
87,162
183,435

103(3,740)+27,112Figures in the table are rounded down

Change(¥):End-FY4/18 compared with end-FY4/17

Cash on hand and in banks
Notes and accounts receivable
Inventories
Total current assets
Buildings and structures,net
Land
Lease assets
Total property,plant andequipment
Goodwill
Lease assets
Total intangible fixed assets
Investments in securities
Deferred tax assets
Deposits and guarantees
Total investments and otherassets
Total deferred assets
Total fixed assets

Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits andguarantees) totaled ¥5,311million■Liabilities and Net Assets(¥ million)
End-FY4/16

End-FY4/17

Total liabilities and net assets

39,9875,690668
66,744
14,854
1,198
19,81886,5638,682
6,367
38,60553,23753,324
139,888

Figures in the table are rounded down

Change(¥):End-FY4/18 compared with end-FY4/17

Accounts payable
Short-term debt
Lease obligations
Total current liabilities
Long-term debt
Lease obligations
Total long-term liabilities
Total liabilities
Common stock
Capital surplus
Retained earnings
Total shareholders’ equity
Total net assets

39,325
7,596
594
72,955
18,254958
23,18896,1448,682
6,367
45,28659,91860,178156,323

End-FY4/18-5-

38,7286,717
443
70,235
11,511
632
16,46786,702
21,89420,50054,26896,662
96,733
183,435

Change
(597)
(879)
(151)
(2,720)(6,743)(326)(6,721)(9,442)+13,212+14,133+8,982+36,744+36,555+27,112

6. FY4/19 Plan (Consolidated)(¥ million)
FY4/17
results

FY4/18results

YoYchangeFY4/19plan

YoYchange (%)

Net sales

248,110

268,385

272,870+4,485+1.7

Gross profit

42,092

47,99348,040+47+0.1% of net sales

17.0

17.9

17.6

27,52928,37030,540+2,170

+7.6

11.1

10.6

11.2

14,563

19,622

17,500(2,122)(10.8)

5.9

7.3

6.4

15,08020,12918,000(2,219)(10.6)

6.1

7.5

6.6

7,949

10,5679,260(1,307)(12.4)

3.2

3.9

3.4

Earnings pershare(¥)

250.71310.08261.38(48.70)(15.7)

Annual dividend (¥)

50.00

50.00

55.00

+5.00

+10.0

SG&A expenses% of net sales

Operating income% of net sales

Ordinary income% of net sales

Profit attributableto owners of parent% of net sales

Figures in the table are rounded down
Change(¥):FY4/19 plan compared with FY4/18 results-6-7. Transition of Store Openings■Number of Store Openings in Dispensing Pharmacy Business
FY4/10 FY4/11 FY4/12 FY4/13 FY4/14 FY4/15 FY4/16 FY4/17 FY4/18Organic

211827383640322725

M&A335283826119110

182

11Total397448494560616754881

1,0661,029

Total number of stores includes temporarily closed stores from FY4/11.

■Number of Store Openings in Cosmetic and Drug Store Business
FY4/10 FY4/11 FY4/12 FY4/13 FY4/14 FY4/15 FY4/16 FY4/17 FY4/18
Organic

567733594Total

49

53

56

6159

56

5252

48

Inquiries related to this presentation should be addressed toAIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
http://www.ainj.co.jp/
This document may not be reproduced or distributed to any third party without
prior approval of AIN HOLDINGS INC. This document has been prepared for
information purpose only and does not form part of a solicitation to sell orpurchase any securities. Information contained herein may be changed orrevised without prior notice. This document may contain forecasting statements
as to future results of operations. No forecast statement can be guaranteed andactual results of operations may differ from those projected.

-7-